Objective There is a global call for formulations, which are better suited for children of different age categories and in a variety of settings. One key public health area of interest is age-appropriate paediatric antibiotics. We aimed to identify clinically relevant paediatric formulations of antibiotics listed on pertinent formularies that were not on the WHO Essential Medicines List for Children (EMLc). Methods We compared four medicines lists versus the EMLc and contrasted paediatric antibiotic formulations in relation to administration routes, dosage forms and/or drug strengths. The additional formulations on comparator lists that differed from the EMLc formulations were evaluated for their added clinical values and costs. Results The analysis was based on 26 EMLc antibiotics. Seven oral and two parenteral formulations were considered clinically relevant for paediatric use. Frequently quoted benefits of oral formulations included: filling the gap of unmet therapeutic needs in certain age/weight groups ( phenoxymethylpenicillin and metronidazole oral liquids, and nitrofurantoin capsules), and simplified administration and supply advantages (amoxicillin dispersible tablets, clyndamycin capsules, cloxacillin tablets, and sulfamethoxazole+trimethoprim tablets). Lower doses of ampicillin and cefazolin powder for injection could simplify the dosing in newborns and infants, reduce the risk of medical errors, and decrease the waste of medicines, but may target only narrow age/ weight groups. Conclusions The identified additional formulations of paediatric antibiotics on comparator lists may offer clinical benefits for low-resource settings, including simplified administration and increased dosing accuracy. The complexity of both procuring and managing multiple strengths and formulations also needs to be considered.
INTRODUCTION
Millions of children die every year from preventable or treatable infections, such as pneumonia, diarrhoea, malaria, tuberculosis, HIV/AIDS and neonatal complications. 1 2 Many of these deaths could be avoided with the use of safe and affordable age-appropriate medicines. 3 4 The response to medications in children is different from that of adults, and it may also vary across age groups due to their development phases. 5 6 That implies that strengths and dosing regimens, tablet sizes and volume of parenteral medicines need to be well adapted to children's age. [7] [8] [9] [10] As a global action to improve access to childspecific medicines, the WHO Essential Medicines List for Children (EMLc) was released on the 30th anniversary of the general EML in 2007. 11 Essential medicines are those that satisfy the priority healthcare needs of the population. They are selected based on public health relevance, evidence on clinical efficacy and safety, and comparative cost-effectiveness. 12 Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford.
12 So, the aim of the EMLc is to recognise special needs for medicines in children, and to promote the inclusion of paediatric medicines in national procurement programmes. 11 Even with these systematic efforts to respond to paediatric therapeutic needs, more work lies ahead. 13 One key public health area of interest in the field of infectious diseases are child-specific antibiotics, due to their potential to fight bacterial infections, including pneumonia and neonatal sepsis that are among leading causes of death in early life. 3 14-16 A first step in improving the availability of age-appropriate formulations of paediatric antibiotics is to obtain up-to-date information if more formulations exist globally, but are not on the EMLc. Therefore, the aim of this study was to compare the antibiotic formulations on relevant medicines lists versus the EMLc, and identify potential new clinically relevant products for paediatric use in lowresource settings. [17] [18] [19] [20] The first three medicine lists originate from high-income countries, which are known for their comprehensive, high quality healthcare systems and good availability of paediatric medicines. The MSH/WHO guide corresponds to a global burden of diseases in children. The fifth edition of the EMLc from 2015 was used as a standard reference list for our comparison. 13 The analysis focused on EMLc antibiotics in section 6: Anti-infectives, subsection 6.2: Antibacterials (6.2.1: β-lactam medicines and 6.2.2: Other antibacterials). 13 21 For the purpose of our comparison, three parameters were used to define the formulations: (1) administration routes, (2) dosage forms and (3) drug strengths. We assessed whether the formulations on the comparator lists differed from the EMLc formulations in any of the parameters. Our findings were arranged to indicate how many EMLc formulations per antibiotic were missing on each of the lists, and how many formulations were an addition to the EMLc.
METHODS
Importantly, EMLc employs the main terms for oral solid dosage forms, such as tablets, capsules, and so on. Thus, the comparison was made at the EMLc level of detail, although comparator lists are more specific (ie, scored, crushable, chewable, dispersible tablets). Besides, our interest was on the lower paediatric age bands, as the EMLc corresponds to clinical needs of children up to 12 years of age, and comparator lists mostly refer to children up to 18 years.
The additional formulations on the comparator lists that differed from the EMLc formulations were extracted for further analysis. They were checked for their compliance with WHO rules on age and weight restrictions-which are established on the basis of drug efficiency and safety data within the age/weight ranges, suitable administration routes, and/or drug content, as described in the WHO model formulary (MF) for children. 21 Ultimately, formulations that countered WHO rules, and/or had been excluded on similar grounds from previous EMLc (2007-2013) were disqualified. The remaining formulations were evaluated for their relevance in paediatric care according to: (1) formulations' added value in clinical practice (ie, unmet needs in certain age/weight group, easier dosing or drug administration, and disease importance) and (2) logistical, supply chain and financial advantages (ie, no need for refrigeration/cold chain, and less drug wastage). Three authors (CR, EZ, MWP) independently appraised all potential new formulations for their relevance, and documented each opinion in a narrative form. Inter-rater agreements were calculated.
The relevance of each formulation was categorised into four groups by author VI: (1) major relevance (unmet needs in certain age/weight group), (2) medium relevance (easier dosing or drug administration, no need for refrigeration/cold chain, less drug wastage), (3) little relevance (narrow age range, few therapeutic indications), and (4) no relevance (unreliable drug administration, uncommon formulation use). A randomly selected subset of six formulations was scored independently by author AKM-T to validate the scoring.
Finally, all EMLc antibiotics were classified into five categories: (1) The remaining 13 antibiotics with 18 new potential WHO-compatible formulations were selected for the clinical evaluation. Seven antibiotics had formulations with an oral, seven with a parenteral and one with a rectal route. The clinical evaluation of these potential new formulations is summarised in table 2. The inter-rater agreement in the assessment of formulations' relevance was around 83% (82% for oral and other formulations, and 85% for injectables). The scoring of formulations by author AKM-T showed no discrepancies in categorisation between the two authors.
All seven oral formulations were considered to have major or medium added value for improved use of antibiotics in children. Frequently quoted reasons for clinical benefits included: filling the gap of unmet therapeutic needs in certain age/weight groups ( phenoxymethylpenicillin oral liquid, metronidazole oral liquid and nitrofurantoin capsules), and simplified administration and logistical and supply chain advantages (amoxicillin dispersible tablets, clindamycin capsules, cloxacillin tablets and sulfamethoxazole+trimethoprim tablets).
The judged value of parenteral formulations for the EMLc ranged from no to medium value. The existing doses of injections on the EMLc were generally seen as sufficient for all ages. For ampicillin and cefazolin powder for injection, lower doses were expected to simplify the dosing in younger children, reduce the risk of medical errors, and decrease the waste of medicines. The drawbacks included: narrow target age/weight groups for the new strengths, and impractical supply system burdened with non-availability, high prices and non-reimbursement. The formulations with new administration routes (doxycycline injections, gentamycin intrathecal injections and intravenous infusion, metronidazole suppositories) were not recommended for clinical practice due to their uncommon use, age restrictions or unreliable drug absorption routes (table 2) .
The final classification of additional antibiotic formulations according to their clinical relevance is presented in table 3. Nine antibiotic formulations were considered to be clinically relevant for paediatric use, while seven formulations were classified to have little or no clinical relevance.
Regarding prices, the identified lower strengths injections on the comparator lists cost the same (ampicillin), or twice less (cefazolin) compared with the twice higher strength phials on the EMLc. The prices of all six oral formulations from the comparator lists were available, except for clindamycin capsules. They show that two formulations (metronidazole, sulfamethoxazole+trimethoprim) have costs similar to the twice higher strength formulations on the EMLc, three formulations ( phenoxymethylpenicillin, amoxicillin, cloxacillin) cost twice as less as the higher strength formulations and one formulation (nitrofurantoin) costs twice as much (table 4) .
DISCUSSION AND CONCLUSIONS
This study provides an overview of the differences in age-appropriate formulations of paediatric antibiotics between four comparator lists and the EMLc.
In summary, seven oral formulations from the comparator lists were regarded as potential solutions for better tolerated and more efficient therapy, since they simplify drug administration Lower strength injection would be appropriate for younger children.
Cloxacillin powder for injection 250 mg Little Lower strength injection would be appropriate for younger children, but it has minor clinical relevance. Ceftriaxone powder for injection 500 mg Ceftazidime powder for injection 500 mg No value It is a proposed new route, but oral forms are sufficient. It has few indications for use in children, and it is age restricted. Gentamycin intrathecal injection 5 mg/mL, and intravenous infusion 800 mg/mL, 1 mg/mL, 3 mg/mL
No value
No added value of infusion bags/intrathecal formulation, the available injection strengths suffice for all children.
Other formulations
Metronidazole suppository 500 mg No value It is a proposed new route in case of vomiting or refusal of oral liquids. It is unsuitable for initiating treatment of serious conditions, due to slow absorption and low plasma concentrations.
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and enhance dosing accuracy in children. Two lower strength oral liquids could be used in children below 4 years of age, who currently have unmet needs for suitable EMLc formulations. Five solid oral forms were seen as alternatives for the oral liquids on the EMLc in children with no swallowing difficulties. Their advantages include accurate dosing, stability, taste masking, easy transport and no need for manipulation before use. 22 23 Dispersible tablets (DTs) may add to the treatment possibilities as they are palatable and easy to administer in younger children with swallowing difficulties. This is in line with the WHO statement in 2008 that flexible oral solid formulations are most optimal formulations for use in children, particularly in lower-income, middle-income countries. 24 25 Amoxicillin DT 250 mg is the United Nations new recommended treatment for pneumonia in children under the age of 5 years, and the lower strength DT may further expand paediatric options. 3 Parenteral antibiotics are important for paediatric, and especially neonatal care, but our clinical assessments put less value on their clinical benefits. 26 27 As indicated, while lower doses of injections may simplify the dosing in neonates and infants, and reduce the waste of medicines, the target age/weight groups for the new strengths may be too narrow.
It is also important to consider the financial implications that these new formulations may have for low-income countries. Our cost comparisons between corresponding antibiotic formulations showed that half of all new oral and parenteral formulations could decrease the cost of treatment, and have a favourable budget impact.
The strength of our study is the use of diverse lists to depict existing therapeutic options globally. The main limitations are the small sample of evaluators and the narrative description of formulations' clinical relevance, although a high inter-rater agreement was reached. Our evaluation criteria and the proposed categorisation represent an early attempt to translate relevant clinical principles into measurable operational components. Further development of a user-friendly instrument, and its validation and testing are needed to verify our tool's consistency and reliability.
Besides the aforementioned benefits, introducing more formulations on the lists may lead to a complex procurement of multiple strengths and formulations, and less efficient drug management, including prescribing. 12 The EMLc is not envisaged as a comprehensive list of all marketed formulations and strengths for children. Nonetheless, it is important to find a suitable platform to share up-to-date information about available age-appropriate paediatric formulations and their advantages and shortcomings, and advocate for their rational use in line with relevant formularies and treatment guidelines. Besides, it is vital to consider the barriers for the implementation of new formulations at the field level, as listing in the WHO EML does not always translate into demand for the medicines at country level. [28] [29] [30] Concluding, the present study identified relevant age-appropriate formulations of paediatric antibiotics that exist. The progress made in developing new formulations needs to be extended for the benefit of children globally. 
